TORONTO

多伦多

,

，

Oct. 28, 2026

2026年10月28日

/PRNewswire/ -- Transpharmation Ltd., a science-led global leader in neuroscience, pain and metabolic disease preclinical contract research, is pleased to announce its acquisition of OrganoTherapeutics SARL, a leader in patient-derived organoid technologies that advance the discovery and development of novel therapies for neurodegenerative/ CNS disorders..

/美通社/ -- 以科学为驱动的全球神经科学、疼痛和代谢性疾病临床前合同研究领导者 Transpharmation Ltd. 欣然宣布收购 OrganoTherapeutics SARL。后者是患者来源类器官技术领域的领军企业，致力于推动神经退行性疾病及中枢神经系统疾病新型疗法的发现与开发。

Following decades of slow progress, discovery in the neurodegenerative space has entered a new era. Our understanding and treatment of debilitating diseases such as Alzheimer's and Parkinson's is rapidly transforming as we are seeing worldwide breakthroughs in genetics, biomarkers, patient-derived cellular models, organoids and translational neuroscience..

在经历了数十年的缓慢进展之后，神经退行性疾病的发现已进入一个新时代。随着我们在遗传学、生物标志物、患者来源的细胞模型、类器官以及转化神经科学领域取得全球性突破，我们对阿尔茨海默病和帕金森病等致残性疾病的认知与治疗正在迅速变革。

Commenting on the acquisition, Dr. Mark Duxon, CEO of Transpharmation Ltd., stated: 'Transpharmation has built a reputation for translational in vivo pharmacology over the last 25 years. With the acquisition of OrganoTherapeutics we are taking our first step in the fulfilment of our ambition to build translational CRO services that include human tissues and systems.

在评论此次收购时，Transpharmation Ltd. 首席执行官马克·杜克森博士表示：“在过去25年中，Transpharmation 在转化体内药理学领域建立了良好的声誉。通过收购 OrganoTherapeutics，我们迈出了实现自身愿景的第一步，即构建包含人体组织和系统的转化型合同研究组织（CRO）服务。”

We see a clear future for the business in the provision of non-animal models alongside our preclinical pharmacology. Drug discovery requires better prediction of drug action and efficacy prior to clinical trials. We believe that being at the forefront of patient-derived 3D organoid work, particularly in the Neurology space, will help provide our clients with increased confidence in their molecules and targets.'.

我们在提供非动物模型以及临床前药理学服务方面，为业务展现了清晰的前景。药物研发需要在临床试验之前更准确地预测药物的作用与疗效。我们相信，在患者源性3D类器官研究领域处于前沿地位，尤其是在神经病学领域，将有助于增强客户对其分子和靶点的信心。

OrganoTherapeutics will continue to operate as a subsidiary of Transpharmation Ltd., with a seamless transition fostering collaboration to amplify the strength of both organizations. The Co-Founder of OrganoTherapeutics, Dr. Jens Schwamborn, responded by saying: 'Joining Transpharmation is a logical next step for OrganoTherapeutics.

OrganoTherapeutics 将继续作为 Transpharmation Ltd. 的子公司运营，通过无缝过渡促进合作，从而增强双方的实力。OrganoTherapeutics 的联合创始人 Jens Schwamborn 博士回应称：“加入 Transpharmation 是 OrganoTherapeutics 合乎逻辑的下一步。”

Over the last few years, we have built human iPSC-derived brain organoid and assembloid models for Parkinson's, Huntington's, ALS and other neurodegenerative diseases, and we have used them in many studies for pharma and biotech partners. Together with Transpharmation's long experience in translational in vivo pharmacology, we can now offer clients both approaches under one roof and help them to take better decisions earlier in drug development.'.

在过去几年中，我们构建了用于帕金森病、亨廷顿病、肌萎缩侧索硬化症（ALS）及其他神经退行性疾病研究的人源诱导多能干细胞（iPSC）衍生的脑类器官和组装体模型，并在许多与制药和生物技术合作伙伴的研究中应用了这些模型。结合Transpharmation在转化体内药理学方面的丰富经验，我们现在能够为客户提供一站式的双重方法服务，帮助他们在药物开发的早期阶段做出更优的决策。

Through the acquisition, Transpharmation and OrganoTherapeutics will bring together complementary expertise in translational neuroscience and human stem cell-derived organoid technology. The combined capabilities will enable biopharma sponsors to investigate disease biology, validate targets and evaluate novel therapeutics using both advanced human-relevant models and established translational research platforms.

通过此次收购，Transpharmation 与 OrganoTherapeutics 将整合其在转化神经科学和人干细胞来源类器官技术方面的互补专长。合并后的能力将使生物制药赞助商能够利用先进的人类相关模型和成熟的转化研究平台，研究疾病生物学、验证靶点并评估新型疗法。

By integrating these approaches, Transpharmation aims to provide a more predictive path from discovery to development and help accelerate innovation in neurodegenerative disease research..

通过整合这些方法，Transpharmation 旨在提供一条从发现到开发的更具预测性的路径，并助力加速神经退行性疾病研究的创新。

As researchers gain access to more predictive human-relevant systems and vast biological insights, discoveries are emerging at an increasingly rapid pace. The therapeutic landscape for these areas is in active transformation, and a large team of organoid and neurodegenerative disease experts with a breadth of knowledge in the field provides ideal toolkit for researchers..

随着研究人员能够获取更多具有人类相关性的预测系统和海量的生物学见解，新发现正以前所未有的速度涌现。这些领域的治疗格局正在经历积极变革，一支拥有广泛领域知识的类器官和神经退行性疾病专家团队为研究人员提供了理想的工具包。

About Human Stem Cell-Derived Brain Organoids

关于人干细胞衍生的脑类器官

Brain organoids are miniature, lab-grown models of human brain tissue made from stem cells donated by healthy volunteers or patients. They contain many of the brain's key cell types, so scientists can study brain diseases such as Parkinson's in real human cells and test promising new treatments more effectively before clinical trials..

脑类器官是利用健康志愿者或患者捐赠的干细胞在实验室中培育出的人脑组织微型模型。它们包含许多大脑的关键细胞类型，因此科学家可以在真实的人类细胞中研究帕金森病等脑部疾病，并在临床试验之前更有效地测试有前景的新疗法。

Luxembourg-based OrganoTherapeutics specializes in patient-specific midbrain organoid and assembloid models of Parkinson's, Huntington's, ALS and other neurodegenerative diseases developed from its own research.

总部位于卢森堡的OrganoTherapeutics公司专注于基于其自主研发的、针对帕金森病、亨廷顿病、肌萎缩侧索硬化症（ALS）及其他神经退行性疾病的患者特异性中脑类器官和组装体模型。

About Human-Relevant Models in Neurodegenerative Disease Research

关于神经退行性疾病研究中与人类相关的模型

Neurodegenerative diseases such as Parkinson's, Alzheimer's and ALS slowly damage nerve cells in the brain and spinal cord.

帕金森病、阿尔茨海默病和肌萎缩侧索硬化症等神经退行性疾病会缓慢损害大脑和脊髓中的神经细胞。

Very few treatments can slow them down, and many medicines that looked promising in early lab work have failed once they reached patients. One reason is that traditional research models, such as animals or simple flat layers of cells, don't fully capture how these diseases behave in the human brain..

能够延缓其进展的治疗方法寥寥无几，许多在早期实验室研究中看似有希望的药物一旦进入患者阶段便宣告失败。其中一个原因是，传统的动物模型或简单的二维细胞培养等研究模型无法全面反映这些疾病在人脑中的实际表现。

Human-relevant models help close that gap. Brain organoids are grown from human stem cells, sometimes from a patient's own cells, so researchers can study disease in living human tissue.

与人类相关的模型有助于缩小这一差距。脑类器官由人类干细胞培养而成，有时甚至使用患者自身的细胞，因此研究人员可以在活体人类组织中研究疾病。

When these models are combined with established preclinical approaches, scientists get a clearer picture of how a potential treatment is likely to work in people. That can help researchers make better decisions earlier, cut down on costly late-stage failures, and bring effective therapies to patients sooner..

当这些模型与成熟的临床前方法相结合时，科学家能够更清晰地了解潜在疗法在人体中可能的作用机制。这有助于研究人员在早期做出更优决策，减少代价高昂的后期失败，并让有效疗法更快惠及患者。

About OrganoTherapeutics

关于OrganoTherapeutics

OrganoTherapeutics is a Luxembourg based company that develops and applies human iPSC derived brain organoid and assembloid models for drug discovery in neurological diseases. Founded as a spin-off of the University of Luxembourg, the company works with pharmaceutical and biotech partners. Its midbrain, striatal, cortical and hindbrain models are generated from patient derived and genetically engineered cell lines and reproduce key features of human disease, such as the vulnerability of dopaminergic neurons and the formation of neuromelanin in Parkinson's disease.

OrganoTherapeutics 是一家总部位于卢森堡的公司，致力于开发和应用源自人类诱导多能干细胞（iPSC）的脑类器官和组装体模型，用于神经系统疾病的药物研发。作为卢森堡大学的衍生公司，该公司与制药和生物技术合作伙伴展开合作。其中脑、纹状体、皮层和后脑模型均源自患者来源及基因工程细胞系，能够重现人类疾病的关键特征，例如帕金森病中多巴胺能神经元的易损性以及神经黑色素的形成。

Beyond Parkinson's disease, OrganoTherapeutics runs programs in Huntington's disease, amyotrophic lateral sclerosis, frontotemporal dementia and a range of rare neurological disorders. Its studies cover the full path from model generation and compound testing to imaging, electrophysiology, omics and machine learning-based data analysis..

除帕金森病外，OrganoTherapeutics 还开展了针对亨廷顿病、肌萎缩侧索硬化症、额颞叶痴呆以及一系列罕见神经系统疾病的研究项目。其研究涵盖从模型构建和化合物测试到影像学、电生理学、组学以及基于机器学习的数据分析的全流程。

About Transpharmation

关于 Transpharmation

Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide for researching and delivering life-changing medicines, science will always remain our passion. Our clients benefit from decades of experience in cross-species and cross-therapeutic area translational biology throughout our preclinical services.

Transpharmation 是一家由科学家主导的合同研究组织。我们因研发并交付改变生命的药物而受到全球药物开发商的认可，科学始终是我们的热情所在。在我们的临床前服务中，客户受益于我们在跨物种和跨治疗领域转化生物学方面数十年的经验。

Transpharmation has a strong focus on preclinical evaluation of potential CNS therapeutics including the areas of epilepsy, pain, neurodegeneration, depression, anxiety, schizophrenia and cognition..

Transpharmation 专注于潜在中枢神经系统治疗药物的临床前评估，涵盖癫痫、疼痛、神经退行性疾病、抑郁症、焦虑症、精神分裂症和认知等领域。